Abstract:Piperacillin (PIP) and tazobactam (TAZ) are broad-spectrum beta-lactam antimicrobial agents, which are frequently co-prescribed in intensive care units (ICUs) worldwide. Ibuprofen (IBU) is a potent pain killer which is commonly co-prescribed with PIP and TAZ postoperatively. The combination therapy of PIP, TAZ, and IBU has been administered commonly after surgical procedures to combat aerobic and anaerobic microbes and exert anti-inflammatory and analgesic effects. This study describes, for the first time, the development of a new capillary electrophoresis (CE) method with a photodiode array detector for the simultaneous determination of PIP, TAZ, and IBU in plasma samples. The experimental factors affecting the elution of analytes were carefully optimized. The final analysis was achieved using a fused silica capillary (58 cm effective length and 75 μm ID) and a background electrolyte solution containing a methanol/borax buffer solution (15 mM and pH 9.3) in a ratio of (10 : 90 v/v) with a driving voltage of 30 kV and detection at 210 nm. The relationship between the peak area and concentration was linear from 1 to 200 μg mL-1 for both PIP and TAZ and from 3 to 200 μg mL-1 for TAZ. The method used was thoroughly validated in accordance with the validation requirements set out by the Food and Drug Administration (FDA) for bio-analytical processes. The proposed CE method was employed to conduct pharmacokinetic and bioavailability studies of the drugs in rat models. The pharmacokinetic results revealed that there is a significant impact upon prescribing this combination concurrently when compared to their single administration. To illustrate, the time required to reach their maximum concentrations (T max) was increased by 0.25 h for both PIP and TAZ, whereas it was increased by 0.5 for IBU. When it comes to their maximum concentration (C max), it was increased by 13.7%, 55.5%, and 44% for PIP, TAZ, and IBU, respectively. Furthermore, the bioavailabilities of PIP, TAZ, and IBU were significantly increased by 55.4%, 19.7%, and 35.6%, respectively. These findings require caution when these drugs are co-prescribed as there is a noticeable augmentation in their therapeutic impacts. Additionally, the greenness of the proposed method was assessed by three metric tools. In conclusion, the method is a valuable tool for further studies on drug-drug interaction in humans.

A validated LC-MS/MS method for simultaneous quantitation of piperacillin, cefazolin, and cefoxitin in rat plasma and twelve tissues

Simultaneous Determination of Capilliposide B and Capilliposide C in Rat Plasma by Lc-Ms/Ms and Its Application to A Pk Study

Establishment of an Isotope Dilution Lc-Ms/Ms Method Revealing Kinetics and Distribution of Co-Occurring Mycotoxins in Rats

Simultaneous Determination of Isoniazid, Rifampicin, Levofloxacin in Mouse Tissues and Plasma by High Performance Liquid Chromatography–tandem Mass Spectrometry

Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry.

Development and Validation of an LC-MS/MS Method for AC1LPSZG and Pharmacokinetics Application in Rats.

Lc-Ms/Ms Method for the Simultaneous Determination of Pa-824, Moxifloxacin and Pyrazinamide in Rat Plasma and Its Application to Pharmacokinetic Study

Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice

Quantification of CPT13 in rat plasma using LC–MS/MS for a pharmacokinetic study

Development of an eco-friendly capillary electrophoresis method for the simultaneous determination of piperacillin, tazobactam and ibuprofen in plasma samples: application to a pharmacokinetic study in rats

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Seven Constituents in Rat Plasma and Application in a Pharmacokinetic Study of the Zaoren Anshen Prescription.

An LC-MS/MS method for the simultaneous determination of 18 antibacterial drugs in human plasma and its application in therapeutic drug monitoring

Development and validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of four tertiary alkaloids in rat plasma and its application to a pharmacokinetic study.

Simultaneous Determination of Six Bioactive Components of Astragali Radix in Rat Plasma Using Triple Quadrupole LC/MS and Its Application to a Pharmacokinetic Study

A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat

Simultaneous quantification of icaritin and its novel 3-methylcarbamate prodrug in rat plasma using HPLC-MS/MS and its application to pharmacokinetic study

Validated Lc-Ms/Ms Assay for Quantitative Determination of Deoxypodophyllotoxin in Rat Plasma and Its Application in Pharmacokinetic Study

Simultaneous Absolute Protein Quantification of Seven Cytochrome P450 Isoforms in Rat Liver Microsomes by LC-MS/MS-based Isotope Internal Standard Method

Development of a Sensitive LC–MS/MS Method for Quantification of Coniferyl Ferulate and Its Metabolite Coniferyl Alcohol in Rat Plasma: Application to a Pharmacokinetic Study

The Development and Validation of an LC-MS/MS Method for the Quantification of CZ112, a Prodrug of 9-Nitrocamptothecin in Rat Plasma

An LC MS/MS Method for the Simultaneous Determination of Ten Antimicrobials and Its Application in Critically Ill Patients